Clinical Trials List
2021-12-10 - 2025-10-31
Phase III
Recruiting6
ICD-10I50.20
Unspecified systolic (congestive) heart failure
ICD-10I50.21
Acute systolic (congestive) heart failure
ICD-10I50.22
Chronic systolic (congestive) heart failure
ICD-10I50.23
Acute on chronic systolic (congestive) heart failure
ICD-10I50.30
Unspecified diastolic (congestive) heart failure
ICD-10I50.31
Acute diastolic (congestive) heart failure
ICD-10I50.32
Chronic diastolic (congestive) heart failure
ICD-10I50.33
Acute on chronic diastolic (congestive) heart failure
ICD-10I50.40
Unspecified combined systolic (congestive) and diastolic (congestive) heart failure
ICD-10I50.41
Acute combined systolic (congestive) and diastolic (congestive) heart failure
ICD-10I50.42
Chronic combined systolic (congestive) and diastolic (congestive) heart failure
ICD-10I50.43
Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure
ICD-10I50.9
Heart failure, unspecified
ICD-9428.0
Congestive heart failure
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
Merck Sharp & Dohme LLC
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yu-Cheng Hsieh Division of Cardiovascular Diseases
- WEI-WEN LIN Division of Cardiovascular Diseases
- 王奇彥 Division of Cardiovascular Diseases
- CHIH-HUNG LAI Division of Cardiovascular Diseases
- Tsun-Jui Liu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳韋璁 Division of Cardiovascular Diseases
- Chun-Yuan Chu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Taiwan National PI
Co-Principal Investigator
- Chern-En Chiang 臨床試驗科
- 黃偉銘 Division of Cardiovascular Diseases
- 吳承學 無
- 黃少嵩 無
- Shih-Hsien Sung Division of Cardiovascular Diseases
- 蔡依霖 無
- 張俊欽 無
- Wen-Chung Yu Division of Cardiovascular Diseases
- Hao-min Cheng Division of Cardiovascular Diseases
- 郭泠 無
- 李慶威 Division of Cardiovascular Diseases
- Tse-Min Lu 無
- Tze-Fan Chao 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Left ventricular ejection fraction (LVEF) of ≤40%, assessed within 12 months before randomization by any imaging method.
Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.
A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP), or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.
Exclusion Criteria
Awaiting heart transplantation, is receiving continuous IV infusion of an inotrope, or has or anticipates receiving an implanted ventricular assist device.
Amyloidosis or sarcoidosis.
Primary valvular heart disease requiring surgical procedure or intervention or has undergone a valvular surgical procedure or intervention within 3 months before randomization.
Hypertrophic cardiomyopathy.
Acute myocarditis or Takotsubo cardiomyopathy.
History of heart transplant.
Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia.
Acute coronary syndrome, or undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 3 months before randomization.
History of symptomatic carotid stenosis, transient ischemic attack (TIA), or stroke within 3 months before randomization.
Malignancy or other noncardiac condition limiting life expectancy to <3 years.
Requires continuous home oxygen for severe pulmonary disease.
Interstitial lung disease.
Discontinuation or dose modification of GDMT or vericiguat within 4 weeks before randomization.
Recent history (within the last year) of drug or alcohol abuse or dependence.
The Estimated Number of Participants
-
Taiwan
65 participants
-
Global
6000 participants
